Issue 105

Emerging Innovations in Psychedelic Healthcare

Psychedelic medicines are entering the latter stages of drug development, progressing from Phase II to Phase III trials, with the sector anticipating their approval and arranging for their adoption.

For drug developers this means focussing on commercialisation strategies, identifying the treatment’s expected patient journey and market size, and collaborating with regulators, healthcare providers and payees to maximise treatment accessibility.

They will also need to mitigate potential bottlenecks and create services that promote the therapy’s integration into existing healthcare frameworks.

As the industry approaches significant milestones in the adoption of psychedelic healthcare, PSYCH spoke with decision makers from across the ecosystem.

THE DECRIMINALISATION OF PSYCHEDELIC HEALTHCARE

As research reaches a tipping point, MAPS’ Founder Rick Doblin expects the widespread legalisation of psychedelic medicines by 2035.

NEARLY 50% OF US SUPPORTS PSYCHEDELIC THERAPY

1,800 US citizens participated in a survey on the use of psychedelic-assisted therapy in the context of mental health treatment.

BUSINESS AND INVESTMENT

Lusaris Therapeutics launches with US$60m funding.

MINDCURE reports Q3 2022 financial results.

Analysis of Small Pharma’s expenditure.

The efficacy of ketamine-assisted therapy in depression.

Apex receives approval for at-home psilocybin trial.

Psychedelic medicines to benefit amputee health.

The impact of psilocybin-assisted therapy in mental health disorders.

On Thursday, 17 November, healthcare leaders will converge in London to accelerate innovation in psychedelic medicine.

The event coincides with the release of The Psychedelics as Medicine Report: Fourth Edition, the industry’s leading data and insights publication, and Jefferies 2022 London Healthcare Conference.

To register your interest, please contact grace@psych.global

CONTACT FORM